Trials / Completed
CompletedNCT00004268
Phase II Study of Midodrine for Neurogenic Orthostatic Hypotension
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 300 (planned)
- Sponsor
- National Center for Research Resources (NCRR) · NIH
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
OBJECTIVES: I. Study further the safety and efficacy of the alpha-receptor agonist midodrine in patients with neurogenic orthostatic hypotension. II. Assess the quality of life in these patients with this treatment regimen.
Detailed description
PROTOCOL OUTLINE: This is a partially randomized, multicenter study. Patients receive oral midodrine three times a day during weeks 1 and 3-5, then either oral midodrine or placebo for weeks 6-8. Quality of life is assessed at weeks 3, 6, and 8.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | midodrine |
Timeline
- Start date
- 2001-04-01
- First posted
- 1999-10-19
- Last updated
- 2005-06-24
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00004268. Inclusion in this directory is not an endorsement.